Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Allogene Therapeutics (ALLO) Cash from Operations (2019 - 2025)

Historic Cash from Operations for Allogene Therapeutics (ALLO) over the last 7 years, with Q3 2025 value amounting to -$29.7 million.

  • Allogene Therapeutics' Cash from Operations rose 3270.32% to -$29.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$158.3 million, marking a year-over-year increase of 2713.37%. This contributed to the annual value of -$200.3 million for FY2024, which is 1574.58% up from last year.
  • Allogene Therapeutics' Cash from Operations amounted to -$29.7 million in Q3 2025, which was up 3270.32% from -$39.0 million recorded in Q2 2025.
  • In the past 5 years, Allogene Therapeutics' Cash from Operations registered a high of -$29.7 million during Q3 2025, and its lowest value of -$68.2 million during Q1 2022.
  • For the 5-year period, Allogene Therapeutics' Cash from Operations averaged around -$50.8 million, with its median value being -$49.3 million (2021).
  • As far as peak fluctuations go, Allogene Therapeutics' Cash from Operations crashed by 35549.87% in 2021, and later skyrocketed by 3862.05% in 2025.
  • Over the past 5 years, Allogene Therapeutics' Cash from Operations (Quarter) stood at -$45.4 million in 2021, then crashed by 36.67% to -$62.1 million in 2022, then grew by 13.51% to -$53.7 million in 2023, then skyrocketed by 31.67% to -$36.7 million in 2024, then rose by 19.1% to -$29.7 million in 2025.
  • Its last three reported values are -$29.7 million in Q3 2025, -$39.0 million for Q2 2025, and -$52.9 million during Q1 2025.